title: Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility.
abstract: BACKGROUND
  Patients with clinically amyopathic dermatomyositis (CADM) appear to be at risk for developing cancer and interstitial lung diseases, but population data to confirm this hypothesis are limited. Moreover, CADM presents cutaneous and histological findings that may overlap with subacute cutaneous lupus erythematosus (SCLE).
  
  
  OBJECTIVE
  To determine the association between myositis-specific autoantibodies, myositis-associated autoantibodies and CADM in Spanish patients. In addition, to study the usefulness of these autoantibodies in the differential diagnosis between CADM and SCLE.
  
  
  METHODS
  Serum samples were tested for myositis-specific autoantibodies and myositis-associated autoantibodies through immunoprecipitation and other standardized methods.
  
  
  RESULTS
  Anti-CADM-p140 and anti-p155 antibodies were the only myositis-specific autoantibodies found and were associated with interstitial lung diseases and cancer respectively. No myositis-associated autoantibodies were found in CADM. Moreover, clinical subsets and proportions seemed to differ from Asian cohorts, where anti-CADM-p140 is considered a CADM hallmark antibody and a risk factor for the development of interstitial lung disease. Interestingly, anti-SSA was highly associated with SCLE, whereas no myositis-specific autoantibodies were found in this entity.
  
  
  CONCLUSIONS
  Association between CADM and myositis-specific autoantibodies and differences between CADM and SCLE were tested on a relatively small cohort of patients.
  
  
  CONCLUSIONS
  There is an association between cancer-associated myositis and interstitial lung diseases and their hallmark autoantibodies in our cohort. In addition, the combined determination of myositis-specific autoantibodies and SSA autoantibodies may help to accurately discriminate SCLE from CADM.
authors: Departamento de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, Madrid, Spain; IMMED S.L., Immunological and Medicinal Products, Madrid, Spain.
authors: C
authors: C
authors: Cuesta-Mateos
authors: B
authors: B
authors: Colom-Fernández
authors: I
authors: I
authors: Portero-Sainz
authors: R
authors: R
authors: Tejedor
authors: C
authors: C
authors: García-García
authors: M J
authors: MJ
authors: Concha-Garzón
authors: M E
authors: ME
authors: De las Heras-Alonso
authors: M A
authors: MA
authors: Martínez
authors: C
authors: C
authors: Juarez
authors: C
authors: C
authors: Muñoz-Calleja
mesh_terms: D000328:Adult; D000368:Aged; D051017:Apoptosis Regulatory Proteins / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D003882:Dermatomyositis / Q000175:diagnosis / Q000276:immunology*; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology*; D010455:Peptides / Q000276:immunology*; D013030:Spain; D009218:Myosins
chemical_list: D051017:Apoptosis Regulatory Proteins; D001323:Autoantibodies; D036341:Intercellular Signaling Peptides and Proteins; D009687:Nuclear Proteins; D010455:Peptides; C501597:CADM-140 peptide, human; C407152:MYO18A protein, human; D009218:Myosins